

Cambridge Epigenetix Ltd
The Trinity Building
Chesterford Research Park
Cambridge, UK
CB10 1XL



Tel: +44 (0)1223 800700

3 March 2018

National Centre for Research and Development
Nowogrodzka 47a
00-695 Warsaw
Poland


Letter of intent

It is a pleasure to write in enthusiastic support of the project entitled "**Mapping of cytosine modifications in nucleic acids using AID/APOBEC enzymes**" led by Dr. Lucyna Budzko, which will be implemented at the Institute of Bioorganic Chemistry PAS in Poznan under the LIDER funding program of the National Centre for Research and Development. Since the proposed in the project technology closely matches interests of Cambridge Epigenetix, I am happy to express our readiness to discuss the potential exploitation of the project results.

The proposed project aims to develop novel methods for detection of cytosine modifications in nucleic acids. The project is a continuation of the already published research: *Mutations in human AID differentially affect its ability to deaminate cytidine and 5-methylcytidine in ssDNA substrates in vitro*, *Scientific Reports 2017*. Two months after the paper was published, Cambridge Epigenetix and the Institute of Bioorganic Chemistry PAS signed non-disclosure agreement (NDA) and Cambridge Epigenetix revised IP rights regarding the work. This confirms our strong interest in the proposed technology, however, its further development is necessary to prepare it for an implementation on the market.

Cambridge Epigenetix was founded in 2012 by Professor Sir Shankar Balasubramanian, co-inventor of Solexa sequencing which underpins the market-leading Illumina[®] sequencing technology, and Dr Bobby Yerramilli-Rao. Cambridge Epigenetix is pioneering the epigenetics revolution. We focus on the 5hmC epigenetic modification and have a patent protected platform for detection of highly accurate signatures for a variety of diseases using this mark. Our mission is to change the way medicine is practised by reducing several routine and important diagnostic screening tests to a simple blood draw using the power of the 5hmC epigenetic modification.

Sincerely,



Dr Jason Mellad
CEO